HR 1227, Alternatives to PAIN Act; issues related to CMMIs Cell and Gene Therapy Access model for Sickle Cell Disease.
Literal federal measure citations: HR 1227
2025 · 1st Quarter (Jan 1 - Mar 31)
VERTEX PHARMACEUTICALS INCORPORATED
Filed by EMPIRE CONSULTING GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- EMPIRE CONSULTING GROUP
- Filing UUID
- 41381afa-fddf-488e-b372-601a77922eab
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.